Step-Ups In Device IPOs
This article was originally published in Start Up
Executive Summary
Valuations of independent device IPOs completed in 2002 to date.
You may also be interested in...
Spin-outs Dominate Lagging IPO Market
Risk-wary investors seem to be favoring the financings of firms backed by a larger corporate partner to those going it alone: spin-out related deals have accounted for 82% of 2002's IPO totals to date.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.